Key Highlights

  • 2.6% is the gap between Gilead Sciences (NASDAQ:GILD) at USD 156.38 and its 52-week high of USD 160.51, per published market data at 10:18 a.m. ET on October 16, 2026. The 52-week low is USD 114.02, so shares sit 37.2% above it (own arithmetic).
  • USD 11.183 billion of acquired IPR&D expense, mainly Arcellx, Tubulis and Ouro Medicines, pushed second quarter non-GAAP EPS to a loss of USD 6.75 at Gilead Sciences (NASDAQ:GILD), per the August 4, 2026 release. Excluding the USD 9.08 charge per share, EPS was USD 2.33 (own arithmetic).
  • USD 7.803 billion was second quarter revenue, up 10%, with HIV sales of USD 5.693 billion, up 12%, per the company release. Gilead Sciences (NASDAQ:GILD) raised 2026 product sales guidance excluding Veklury to USD 29.8 billion to USD 30.1 billion.
  • USD 3.179 billion of cash and marketable debt securities remained at June 30, 2026, against USD 10.605 billion at December 31, 2025. The USD 0.82 quarterly dividend yields 2.1%, and results are estimated for October 29, 2026, a date not confirmed by the company.

Price Action and Valuation Context

Gilead Sciences (NASDAQ:GILD) traded at USD 156.38 at 10:18 a.m. ET on October 16, 2026, down 0.63%, inside a 52-week range of USD 114.02 to USD 160.51 per published market data. The RSI of 64.1 is below the 70 overbought threshold, and relative volume was 0.1x early in the session. Shares rose 13.5% from August 4 to October 14, 2026, while SPDR S&P 500 ETF Trust (NYSEARCA:SPY) fell 0.2%. Trailing GAAP EPS is negative, so trailing P/E is not meaningful; on the guidance midpoint excluding the charge, USD 8.61, the multiple is 18.2 times (own arithmetic).

Earnings Quality and Segment Drivers

Acquired in-process research is expensed when a company buys unapproved assets, not capitalised. That is why buying Arcellx, Tubulis and Ouro Medicines cut non-GAAP EPS by USD 9.08 in one quarter and cash by USD 7.426 billion since December 31, 2025 (own arithmetic). Operations held up: operating cash flow was USD 3.573 billion, Biktarvy sold USD 3.772 billion, up 7%, and Trodelvy USD 457 million, up 26%. Veklury fell 81%. Next quarter consensus is USD 2.20 from 22 analysts, per published market data.

Pipeline, Analyst Views and Risks

The FDA approved Trodelvy for first-line triple-negative breast cancer, and the target action date for once-weekly oral Yeztugo for PrEP is February 2, 2027. Phase 3 ISLEND-1 and ISLEND-2 with Merck (NYSE:MRK) were positive, while EVOKE-03 in lung cancer was discontinued. Of 29 analysts, 23 rate the stock Buy and 6 Hold, with an average target of USD 159.33, 1.9% above the quote. Risks: further deal charges and lower cash.

Where Things Stand

It depends. Gilead Sciences (NASDAQ:GILD) can hold its position 2.6% below the 52-week high if the third quarter confirms that the USD 11.183 billion charge is a one-time accounting event, since underlying EPS of USD 2.33 rose from USD 2.01 and product sales guidance was raised. Against that, the average target of USD 159.33 leaves little upside, cash fell to USD 3.179 billion, and shares are up 13.5% since August 4. Results are estimated for October 29, 2026, a date the company has not confirmed in the material reviewed.